Skip to main content
. 2022 Oct 27;10(10):e005471. doi: 10.1136/jitc-2022-005471

Figure 2.

Figure 2

Tumor size change from baseline over time, by RECIST. Lines represent individual patients. Dashed horizontal reference lines at 20% and –30% indicate the thresholds for RECIST V.1.1-defined objective progression and partial response, respectively. (A) Dose escalation and (B) dose expansion. HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; RECIST, Response Evaluation Criteria in Solid Tumors.